title: Stewart-Bluefarb syndrome: review of the literature and case report of chronic ulcer treatment with heparan sulphate (Cacipliq20®).
abstract: Stewart-Bluefarb syndrome (SBS), also known as acroangiodermatitis or pseudo-Kaposi, is a condition rarely encountered. It involves skin lesions that are clinically similar to Kaposi sarcoma but are histologically different, and are usually secondary to an underlying arteriovenous fistula. Treatment of this disease usually involves the correction of the underlying vascular abnormality, with the mainstay of therapy ranging from compression devices for venous stasis, limited oral medications (dapsone and erythromycin) and local wound care including topical steroids. Different methods of treatment showed varied success but none is ideal. We report a case of a lower extremity ulcer in a 22-year-old male recently diagnosed with SBS successfully treated with heparan sulphate (Cacipliq20®).
authors.affiliation: Division of Plastic and Reconstructive Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
authors.forename: Shady
authors.initials: S
authors.lastname: Hayek
authors.forename: Bishara
authors.initials: B
authors.lastname: Atiyeh
authors.forename: Elias
authors.initials: E
authors.lastname: Zgheib
mesh_terms: D000169:Acrodermatitis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D001164:Arteriovenous Fistula / Q000150:complications / Q000175:diagnosis; D002908:Chronic Disease; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D013577:Syndrome; D055815:Young Adult
chemical_list: D006497:Heparan Sulfate
keywords: Acroangiodermatitis; Chronic ulcer; Heparan sulphate; Pseudo-Kaposi; Stewart-Bluefarb syndrome
references.citation: Peptides. 2002 Jul;23(7):1323-32
references.pmid: 12128089
references.citation: J Dermatol. 1997 Jan;24(1):28-33
references.pmid: 9046737
references.citation: J Med. 1995;26(5-6):253-60
references.pmid: 8721902
references.citation: Drug Discov Today. 2010 Dec;15(23-24):1058-69
references.pmid: 20974281
references.citation: J Eur Acad Dermatol Venereol. 2001 Sep;15(5):382-4
references.pmid: 11763372
references.citation: Clin Exp Dermatol. 2008 Jan;33(1):22-5
references.pmid: 17927784
references.citation: Med Microbiol Immunol. 1996 Feb;184(4):155-61
references.pmid: 8811646
references.citation: J Biol Chem. 2005 Sep 23;280(38):32792-800
references.pmid: 16014624
references.citation: Cancer Treat Rep. 1979 Apr;63(4):529-37
references.pmid: 445507
references.citation: FASEB J. 2000 Nov;14(14):2133-4
references.pmid: 11024002
references.citation: Wound Repair Regen. 2009 Nov-Dec;17(6):840-52
references.pmid: 19903305
references.citation: Pediatr Dermatol. 2001 Jul-Aug;18(4):325-7
references.pmid: 11576408
references.citation: Hautarzt. 2000 May;51(5):336-9
references.pmid: 10875071
references.citation: Int Wound J. 2011 Feb;8(1):85-95
references.pmid: 21078132
references.citation: Curr Opin Mol Ther. 2006 Dec;8(6):521-8
references.pmid: 17243488
references.citation: C R Acad Sci III. 1995 Oct;318(10):1037-43
references.pmid: 8556449
references.citation: FASEB J. 2004 Jul;18(10):1147-9
references.pmid: 15132978
references.citation: Nat Rev Immunol. 2006 Sep;6(9):633-43
references.pmid: 16917509
references.citation: J Clin Invest. 1997 May 1;99(9):2062-70
references.pmid: 9151776
references.citation: PLoS One. 2010 Jul 21;5(7):e11644
references.pmid: 20657775
references.citation: Int J Low Extrem Wounds. 2007 Jun;6(2):82-97
references.pmid: 17558006
references.citation: J Biomed Mater Res A. 2009 Sep 1;90(3):641-7
references.pmid: 18563829
references.citation: Mol Cancer Ther. 2006 Sep;5(9):2139-48
references.pmid: 16985046
references.citation: Arch Dermatol. 1979 Jun;115(6):747-8
references.pmid: 453882
references.citation: J Eur Acad Dermatol Venereol. 2001 Sep;15(5):487-9
references.pmid: 11763401
references.citation: J Dermatol. 2009 Jul;36(7):415-8
references.pmid: 19583690
references.citation: J Clin Invest. 2001 Aug;108(3):349-55
references.pmid: 11489925
references.citation: Actas Dermosifiliogr. 2007 Oct;98(8):545-8
references.pmid: 17919429
references.citation: FASEB J. 1999 Apr;13(6):761-6
references.pmid: 10094936
references.citation: Vasa. 2007 May;36(2):134-7
references.pmid: 17708107
references.citation: Nat Immunol. 2005 Sep;6(9):861-2
references.pmid: 16116461
references.citation: Chem Biol Drug Des. 2008 Dec;72(6):455-82
references.pmid: 19090915
references.citation: Am J Clin Dermatol. 2007;8(2):61-6
references.pmid: 17428110
references.citation: Acta Derm Venereol. 1995 Nov;75(6):475-8
references.pmid: 8651028
references.citation: Infect Immun. 1997 Jan;65(1):1-8
references.pmid: 8975885
references.citation: Curr Med Chem. 2006;13(15):1799-810
references.pmid: 16787222
references.citation: Int J Dermatol. 1998 Mar;37(3):223-5
references.pmid: 9556115
references.citation: Br J Dermatol. 1996 Jan;134(1):44-6
references.pmid: 8745885
references.citation: Int J Dermatol. 2005 Feb;44(2):136-8
references.pmid: 15689214
references.citation: J Neurosurg. 2008 Nov;109(5):967-73
references.pmid: 18976093
references.citation: Australas Radiol. 2001 May;45(2):225-7
references.pmid: 11380370
references.citation: J Cutan Pathol. 1999 Mar;26(3):159-64
references.pmid: 10235383
references.citation: J Biomed Mater Res A. 2007 Jan;80(1):75-84
references.pmid: 16958049